• ChemFaces is a professional high-purity natural products manufacturer.
  • Product Intended Use
  • 1. Reference standards
  • 2. Pharmacological research
  • 3. Inhibitors
  • Home
  • Natural Products
  • Bioactive
  • Screening Libraries
  • Hot Products
  • Plant Catalog
  • Customer Support
  • Product Use Citation
  • About Us
  • Contact Us
  • Natural Products
    Pramipexole dihydrochloride
    Pramipexole dihydrochloride
    CAS No. 104632-25-9 Price
    Catalog No.CFN90019Purity>=98%
    Molecular Weight284.25Type of CompoundAlkaloids
    FormulaC10H19Cl2N3SPhysical DescriptionPowder
    Download     COA    MSDSSimilar structuralComparison (Web)
    How to Order
    Orders via your E-mail:

    1. Product number / Name / CAS No.
    2. Delivery address
    3. Ordering/billing address
    4. Contact information
    Sent to Email: info@chemfaces.com
    Contact Us
    Order & Inquiry & Tech Support

    Tel: (0086)-27-84237683
    Fax: (0086)-27-84254680
    E-mail: manager@chemfaces.com
    Address: No. 83, CheCheng Rd., WETDZ, Wuhan, Hubei 430056, PRC
    Delivery time
    Delivery & Payment method

    1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

    2. We accept: Wire transfer & Credit card & Paypal & Western Union
    * Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
    Our products had been exported to the following research institutions and universities, And still growing.
  • Institute of Tropical Disease Un... (Indonesia)
  • Washington State University (USA)
  • Regional Crop Research Institute (Korea)
  • Fraunhofer-Institut für Molekul... (Germany)
  • Srinakharinwirot University (Thailand)
  • University of Melbourne (Australia)
  • Chang Gung University (Taiwan)
  • Weizmann Institute of Science (Israel)
  • Wageningen University (Netherlands)
  • Heidelberg University (Germany)
  • Cornell University (USA)
  • More...
  • Package
    Featured Products

    Catalog No: CFN92252
    CAS No: 510-22-5
    Price: $463/5mg

    Catalog No: CFN90448
    CAS No: 14941-08-3
    Price: $218/20mg

    Catalog No: CFN92207
    CAS No: 22327-82-8
    Price: $338/10mg

    Catalog No: CFN99111
    CAS No: 21967-41-9
    Price: $40/20mg
    Tanshinone IIB

    Catalog No: CFN99820
    CAS No: 17397-93-2
    Price: $463/5mg
    Pramipexole dihydrochloride Description
    Biological Activity or Inhibitors: 1. Pramipexole dihydrochloride could be used to treat Parkinson disease.
    Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
    Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

    After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
    Recent ChemFaces New Products and Compounds

    Catalog No: CFN98172
    CAS No: 479-91-4
    Price: $158/20mg

    Catalog No: CFN92172
    CAS No: 22688-79-5
    Price: $318/10mg
    Kushenol C

    Catalog No: CFN92391
    CAS No: 99119-73-0
    Price: $468/10mg
    Columbianetin beta-D-glucopyranosi...

    Catalog No: CFN95038
    CAS No: 55836-35-6
    Price: $288/5mg

    Catalog No: CFN92016
    CAS No: 53846-50-7
    Price: $298/10mg
    Naringin 4'-glucoside

    Catalog No: CFN95014
    CAS No: 17257-21-5
    Price: $338/5mg
    2-Hydroxy-3-methoxybenzoic acid gl...

    Catalog No: CFN89113
    CAS No: 172377-87-6
    Price: $268/5mg

    Catalog No: CFN95013
    CAS No: 3968-19-2
    Price: $318/10mg
    Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.

    PMID: 29328914

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.

    PMID: 29149595

    Scientific Reports 2017 Dec 11;7(1):17332.
    doi: 10.1038/s41598-017-17427-6.

    PMID: 29230013

    Molecules. 2017 Oct 27;22(11). pii: E1829.
    doi: 10.3390/molecules22111829.

    PMID: 29077044

    J Cell Biochem. 2018 Feb;119(2):2231-2239.
    doi: 10.1002/jcb.26385.

    PMID: 28857247

    Phytomedicine. 2018 Feb 1;40:37-47.

    PMID: 29496173
    Calculate Dilution Ratios(Only for Reference)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.518 mL 17.5901 mL 35.1803 mL 70.3606 mL 87.9507 mL
    5 mM 0.7036 mL 3.518 mL 7.0361 mL 14.0721 mL 17.5901 mL
    10 mM 0.3518 mL 1.759 mL 3.518 mL 7.0361 mL 8.7951 mL
    50 mM 0.0704 mL 0.3518 mL 0.7036 mL 1.4072 mL 1.759 mL
    100 mM 0.0352 mL 0.1759 mL 0.3518 mL 0.7036 mL 0.8795 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    Pramipexole dihydrochloride References Information
    Citation [1]

    J Pharm Biomed Anal. 2006 Jun 16;41(4):1152-6. Epub 2006 Mar 31.

    Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride monohydrate.[Pubmed: 16580170]
    A chiral liquid chromatographic method was developed for the enantiomeric resolution of Pramipexole dihydrochloride monohydrate, (S)-2-amino-4,5,6,7-tetra-hydro-6-(propylamino) benzothiazole dihydrochloride monohydrate, a dopamine agonist in bulk drugs. The enantiomers of Pramipexole dihydrochloride monohydrate were resolved on a Chiralpak AD (250 mm x 4.6 mm, 10 microm) column using a mobile phase system containing n-hexane:ethanol:diethylamine (70:30:0.1, v/v/v). The resolution between the enantiomers was found not less than eight. The presence of diethylamine in the mobile phase has played an important role in enhancing chromatographic efficiency and resolution between the enantiomers. The developed method was extensively validated and proved to be robust. The limit of detection and limit of quantification of (R)-enantiomer were found to be 300 and 900 ng/ml, respectively for 20 microl injection volume. The percentage recovery of (R)-enantiomer was ranged from 97.3 to 102.0 in bulk drug samples of Pramipexole dihydrochloride monohydrate. Pramipexole dihydrochloride monohydrate sample solution and mobile phase were found to be stable for at least 48 h. The proposed method was found to be suitable and accurate for the quantitative determination of (R)-enantiomer in bulk drugs.
    Citation [2]

    Archives of Neurology [01 Jan 2010, 67(1):27-32]

    Effects of a dopamine agonist on the pharmacodynamics of levodopa in Parkinson disease.[Pubmed: 20065126]
    Treatment of Parkinson disease commonly includes levodopa and dopamine agonists; however, the interaction of these 2 drugs is poorly understood. OBJECTIVE: To examine the effects of a dopamine agonist on the motor response to levodopa. DESIGN: Double-blind, randomized, placebo-controlled, crossover clinical trial. SETTING: Ambulatory academic referral center. Patients Thirteen patients with idiopathic Parkinson disease taking levodopa and experiencing motor fluctuations and dyskinesia. INTERVENTIONS: Eligible individuals were randomly assigned to receive Pramipexole dihydrochloride or placebo for 4 weeks followed by a 2-hour intravenous levodopa infusion on consecutive days at 2 rates and with blinded assessments. They were then crossed over to the alternate oral therapy for 4 weeks followed by levodopa infusion and reassessment. MAIN OUTCOME MEASURES: Change in finger-tapping speed, measured using the area under the curve (AUC) for finger taps per minute across time; peak finger-tapping speed; duration of response; time to "ON" (defined as a 10% increase in finger-tapping speed above baseline); walking speed; and dyskinesia AUC. RESULTS: Pramipexole with levodopa infusion increased finger-tapping speed beyond the change in baseline by a mean (SE) of 170 (47.2) per minute x minutes (P = .006) and more than doubled the AUC for finger-tapping speed. Pramipexole increased peak finger-tapping speed by a mean (SE) of 18 (8.5) taps per minute (P = .02) and improved mean (SE) walking speed (15.9 [0.70] vs 18.9 [0.70] seconds, P = .004). Pramipexole prolonged duration of response after levodopa infusion and shortened time to ON. Pramipexole increased mean (SE) baseline dyskinesia scores (26.0 [5.85] vs 12.1 [5.85] points, P = .05) and peak dyskinesia scores with levodopa infusion. CONCLUSIONS: Pramipexole augmented the motor response to levodopa beyond a simple additive effect and increased the severity of levodopa-induced dyskinesia. When considering a combinat